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ABSTRACT
Background: Patients with pulmonary arterial
hypertension (PAH) are managed according to
evidence-based treatment guidelines.
Methods and results: In this single-centre
retrospective analysis, we examined outcomes of
patients with PAH caused by congenital heart disease
(PAH-CHD) with respect to exercise capacity and
survival of adults treated with either bosentan or
sildenafil monotherapy or bosentan-sildenafil dual
therapy between January 2007 and January 2014. Of
the 82 patients analysed, 29 had Down syndrome; 54
(65.8%) received bosentan monotherapy, 16 (19.5%)
sildenafil monotherapy and 12 (14.6%) dual therapy.
Mean treatment duration was 2.5 years for all patients
and 4.1 years for 38 patients treated for ≥2 years.
Pooled patient and treatment data showed initial
improvement followed by stabilisation in mean 6 min
walk distance (6MWD). For Down and non-Down
patients, mean 6MWD increased and then stabilised on
bosentan monotherapy. Mean 6MWD of patients on
dual therapy at the time of analysis was 246.3 m
before PAH-specific therapy initiation, 211.9 m
immediately prior to addition of a second therapy and
214.4 m at last visit while on dual therapy. 1, 2 and 3-
year survival rates for all patients from time of
treatment initiation were 96%, 87% and 80%,
respectively.
Conclusions: For the majority of patients,
monotherapy with a PAH-specific medication provided
improved and sustained exercise benefits. For the small
percentage of patients who required it, add-on therapy
appeared to prevent further deterioration in exercise
capacity but did not improve 6MWD.
INTRODUCTION
Up to 10% of patients born with heart
defects that result in an incomplete separ-
ation of the systemic and pulmonary circula-
tions develop the secondary condition of
pulmonary arterial hypertension (PAH).1 2
The consequences of PAH associated with
congenital heart defects (PAH-CHD) can be
serious with the respective risk of mortality
and morbidity being twofold and threefold
higher in patients with PAH-CHD compared
with those without PAH.3 Symptomatically,
patients with PAH typically experience dys-
pnoea, fatigue, chest pain and occasionally
presyncope on exertion. Such symptoms
often interfere with everyday tasks that entail
physical activity.4 Oral PAH therapies, such as
sildenaﬁl (a phosphodiesterase inhibitor)
and bosentan (an endothelin receptor antag-
onist (ERA)) have been shown in clinical
trials to improve exercise capacity in patients
with PAH,5–7 including those with PAH-
CHD.8 While the majority of patients with
PAH are initially treated with monotherapy,
newer guidelines recommend combining
drugs from different classes in patients who
fail to have an adequate response to initial
therapy.9 10 Real-life data from registries or
single-centre patient databases have shown
KEY QUESTIONS
What is already known about this subject?
▸ Long-term monotherapy with bosentan has been
shown to result in sustained symptomatic bene-
fits in patients with pulmonary arterial hyperten-
sion (PAH) caused by congenital heart disease
(PAH-CHD), particularly in those without Down
syndrome.
What does this study add?
▸ This study expands on previous findings and
demonstrates that in the proportion of patients with
PAH-CHD who deteriorate on monotherapy, com-
bination therapy can prevent further deterioration.
How might this impact on clinical practice?
▸ For those patients who show a decline in exercise
capacity after a period of stabilisation with mono-
therapy, addition of a second oral PAH-specific
drug may help limit further deterioration.
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that the use of combination therapy ranges from 46–
75% in patients with idiopathic PAH,11 12 to 29–50% in
patients with PAH associated with connective tissue
disease13 14 and 17–32% in patients with PAH-CHD due
to large unrepaired defects.15 In our centre, patients are
treated in accordance with currently available evidence-
based guidelines, with ERAs generally used as ﬁrst-line
therapy in patients with Eisenmenger’s syndrome. Here,
we conducted a retrospective single-centre analysis of
adults with PAH-CHD who received bosentan or sildena-
ﬁl monotherapy, or dual bosentan and sildenaﬁl
therapy. The aim was to examine outcomes in terms of
symptomatic improvements based on exercise capacity
and survival from treatment initiation.
METHODS
Data on all patients (≥18 years old; with and without
Down syndrome) with PAH-CHD who were referred to,
and received PAH therapy, at the tertiary adult congeni-
tal cardiac centre at the Manchester Royal Inﬁrmary,
UK, were prospectively collected in a dedicated data-
base. All data were collected as part of submission for
the national UK database, which is mandatory for UK
centres treating pulmonary hypertension patients. All
non-Down syndrome patients, apart from one who
refused to give consent, were diagnosed via right heart
catetherisation (RHC), which conﬁrmed the presence of
severe PAH. Given the requirement to perform RHC
under general anaesthesia in patients with Down syn-
drome, diagnosis for these patients was instead via echo-
cardiography together with clinical signs and symptoms.
Data included patient demographics, underlying cardiac
diagnoses, WHO functional class, concomitant iron
replacement therapy, initiation of PAH-speciﬁc medica-
tion, 6 min walk distance (6MWD), oxygen saturations
(measured using pulse oximetry or via blood sampling)
at rest and postwalk test, laboratory measurements of
aspartate aminotransferase (AST), γ glutamyl transferase
(GGT), haemoglobin and platelet levels, and all-cause
mortality.
All patients treated with bosentan and/or sildenaﬁl
between January 2007 and January 2014 were included
in this analysis. Routine vasoreactivity was not carried
out unless it was felt that PAH was reversible. On the
basis of clinical history and CHD diagnosis, most cases
in this retrospective analysis were judged to be not
reversible. Bosentan was initiated at 62.5 mg twice daily
for the ﬁrst 4 weeks and, tolerability permitting, titrated
up to 125 mg twice daily thereafter. Sildenaﬁl was
initiated at a dose of 25 mg two to three times a day and
uptitrated as clinically indicated and tolerated.
Consistent with evidence-based guidelines, an ERA was
generally chosen as ﬁrst-line therapy. In the event of a
lack of improvement in functional class (no change
from class III to II or I) or if 6MWD fell by 20% from
last visit then patients were switched from monotherapy
to bosentan-sildenaﬁl dual therapy.
All patients provided verbal consent to receive treat-
ment as part of their routine care and hence consent
was not formally documented. Patient data were col-
lected by the adult congenital nurse specialist from the
unit and were anonymised by the adult congenital nurse
specialist and another study author. The adult congeni-
tal nurse specialist had access to patient identifying
information but none of those who analysed the data
had access to this information. As the lead clinician for
the service, one of the study authors interacted with and
treated the patients. This is a retrospective analysis of an
existing database which collects routine clinical care
data, and forms part of the national UK database, which
is mandatory for UK centres treating pulmonary hyper-
tension. As this was not a prospective study but a retro-
spective analysis of existing data, approval from an
Institutional Review Board or ethics committee was not
sought.
Data were analysed for all patients and by Down syn-
drome status, as well as according to treatment regimen,
that is, monotherapy with either bosentan or sildenaﬁl,
or bosentan-sildenaﬁl dual therapy following an initial
period of monotherapy with either drug. Data were ana-
lysed at baseline (ie, prior to initiation of therapy), and
visits 1, 2, 3, 4 and 5, which approximately corresponded
to months 3, 6, 12, 18 and 24, and latest visit. Data were
considered missing if a visit was missed. For patients on
dual therapy at the time of data analysis and because of
the variability of monotherapy and dual therapy treat-
ment periods, data for 6MWD were analysed at baseline
(ie, prior to initiation of monotherapy treatment), at the
time point prior to dual therapy initiation and at the
time point of last visit. Patients who received dual
therapy following a period of monotherapy were not
included in the monotherapy analysis.
Treatment duration was deﬁned from the date of treat-
ment initiation to date of last available visit and was also
calculated for patients who had data post-month 24.
Treatment duration for patients on monotherapy was
from date of treatment initiation to date of last available
visit. For patients on dual therapy at the time of data
analysis, the initial monotherapy treatment duration was
from the date of treatment initiation for ﬁrst therapy to
date of commencement of second therapy, while dual
treatment duration was from the date of commence-
ment of second therapy to date of last available visit.
Data were analysed using SAS 9.4 (SAS Institute, Cary,
North Carolina, USA). Observed data only were
included in the analyses and imputations for missing
data were not made. Categorical data were described by
frequency and percentage; continuous data were sum-
marised by their means and SD, or median and range.
Age between Down and non-Down patients was com-
pared using a two-sample t test assuming unequal var-
iances (Satterthwaite method). 6MWD at baseline by
treatment group for patients by Down syndrome status
was compared using a one-way analysis of variance
(ANOVA), adjusting for treatment. A multivariate
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random effects repeated measures ANOVA model with
random intercept and time terms (linear and, if applic-
able, quadratic) was used to estimate change in 6MWD
from baseline for all patients and by Down syndrome
status regardless of treatment regimen, and for patients
on bosentan monotherapy by Down syndrome status. A
similar model, adjusting for time as a linear term
(random intercept and slope), was used to assess change
in prewalk test oxygen saturations from baseline and
change in the difference pre to postwalk test in oxygen
saturation over time for all patients. For patients on dual
therapy at the time of data analysis, difference in 6MWD
at baseline prior to the initiation of monotherapy and last
visit and the point prior to initiation of a second therapy
and last visit were tested for using the paired t test.
Signiﬁcance was set at p<0.05. Kaplan-Meier plots
provided an estimate of survival from time of treatment
initiation to last available visit. Patients who survived were
censored at the January 2014 cut-off date. Survival data
from patients with Down syndrome in comparison to
those without Down syndrome were not subject to a
log-rank test.
RESULTS
The database included 82 patients with PAH-CHD, of
whom 29 had Down syndrome, who had received PAH-
speciﬁc medication at our centre. Demographics and
baseline characteristics are shown in table 1. Average age
was 38.1±14.0 years and most (58.5%) patients were
female. Patients with Down syndrome were signiﬁcantly
younger than those without Down syndrome (33.9±8.4 vs
Table 1 Demographics, baseline characteristics and on-treatment parameters for all patients and by Down syndrome status
Parameter All patients (n=82)
Non-Down syndrome
patients (n=53)
Down syndrome
patients (n=29)
Mean±SD age at first visit, years (range) 38.1±14.0 (18–81) 40.3±15.9 (18–81) 33.9±8.4 (21–53)
Male/Female, n (%) 34 (41.5)/48 (58.5) 21 (39.6)/32 (60.4) 13 (44.8)/16 (55.2)
Congenital heart defect in patients with Eisenmenger syndrome, n (%)
Total 52 (63.4) 26 (49.1) 26 (89.7)
ASD 3 (5.8) 3 (11.5) 0 (0)
VSD 17 (32.7) 9 (34.6) 8 (30.8)
AVSD 16 (30.8) 1 (3.8) 15 (57.7)
PDA 4 (7.7) 4 (15.4) 0 (0)
TGA 1 (1.9) 1 (3.8) 0 (0)
VSD and TGA 2 (3.8) 2 (7.7) 0 (0)
VSD and PDA 3 (5.8) 2 (7.7) 1 (3.8)
AVSD and TGA 1 (1.9) 1 (3.8) 0 (0)
AVSD and PDA 2 (3.8) 0 (0) 2 (7.7)
VSD and TGA and TA 1 (1.9) 1 (3.8) 0 (0)
Aortopulmonary window 2 (3.8) 2 (7.7) 0 (0)
Congenital heart defect in patients without Eisenmenger syndrome, n (%)
Total 30 (36.6) 27 (50.9) 3 (10.3)
ASD 3 (10.0) 3 (11.1) 0 (0)
VSD 5 (16.7) 4 (14.8) 1 (33.3)
AVSD 4 (13.3) 2 (7.4) 2 (66.7)
PA 1 (3.3) 1 (3.7) 0 (0)
TA 2 (6.7) 2 (7.4) 0 (0)
TGA 3 (10.0) 3 (11.1) 0 (0)
TrA 1 (3.3) 1 (3.7) 0 (0)
VSD and PA 4 (13.3) 4 (14.8) 0 (0)
VSD and TGA 2 (6.7) 2 (7.4) 0 (0)
AVSD and TGA 1 (3.3) 1 (3.7) 0 (0)
VSD and TA and TGA 1 (3.3) 1 (3.7) 0 (0)
AVSD and TA and PDA 1 (3.3) 1 (3.7) 0 (0)
Not recorded 2 (6.7) 2 (7.4) 0 (0)
WHO Functional Class (I–IV) III III III
Mean±SD 6MWD at baseline, m
(median (range))
254.1±106* (270
(29–480)*)
278±102* (281 (29–480)*) 214±102 (210 (30–405))
Mean±SD treatment duration, years
(median (range))
2.5±1.9 (2.4 (0.0–
6.9))
2.8±1.9 (2.6 (0.0–6.1)) 2.0±1.8 (1.4 (0.0–6.9))
Iron replacement therapy, n (%) 11 (13.4) 7 (13.2) 4 (13.7)
*Baseline 6MWD unavailable for four patients.
6MWD, 6 min walk distance; ASD, atrial septal defect; AVSD, atrioventricular septal defect; PA, pulmonary atresia; PDA, patent ductus
arteriosus; TA, tricuspid atresia; TGA, transposition of the great arteries; TrA, truncus arteriosus; VSD, ventricular septal defect.
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40.3±15.9 years; p=0.02). The majority of patients had
Eisenmenger syndrome (n=52; 63.4%), with ventricular
septal defect (n=22; 26.8%) and atrioventricular septal
defects (n=20; 24.4%) being the most common defects.
All patients were in WHO functional class III prior to
the start of treatment. As most patients had uncorrected
defects that were considered unsuitable for repair and,
additionally, were judged to have non-reversible PAH,
vasoreactivity tests were not undertaken. Thus, it was not
possible to measure vasoreactivity in these patients and
assess its relationship to therapeutic response.
Patients were treated with either bosentan (n=54) or
sildenaﬁl monotherapy (n=16), or bosentan-sildenaﬁl
dual therapy (n=12) after a period of either bosentan
(n=10) or sildenaﬁl (n=2) monotherapy. Mean treat-
ment duration for all patients, regardless of treatment
regimen, was 2.5 years and of longer duration in patients
without Down syndrome than in those with Down syn-
drome, a difference that was most likely attributable to
patients with Down syndrome being younger on average
(table 1). For the 38 patients who were treated beyond
month 24, the mean duration of therapy was 4.1 years.
Durations for each treatment regimen for all patients
and by Down status are shown in table 2.
Iron replacement therapy was prescribed in 11
patients (table 1) and administered concomitantly with
either bosentan monotherapy or dual therapy (table 2).
Administration of iron replacement therapy was similar
in patients without (n=7; 13.2%) and with (n=4; 13.7%)
Down syndrome (table 1).
Patients without Down syndrome had a higher mean
6MWD at baseline (table 1) and at each time point
(ﬁgure 1A) than those with Down syndrome. Following
treatment, 6MWD tended to increase initially and then
stabilise over time, regardless of Down syndrome status.
In patients without Down syndrome the change in
6MWD from baseline was signiﬁcant at time points up to
month 24 and for those with Down syndrome changes
from baseline were signiﬁcant at months 12, 18 and 24
(ﬁgure 1B). 6MWD changed signiﬁcantly over time for all
patients when analysed together (p<0.01) and for patients
without Down syndrome (p<0.01) but not for patients
with Down syndrome (p>0.05).
There were no signiﬁcant differences between 6MWD
at baseline between treatment groups for patients
without Down syndrome. For patients without and with
Down syndrome, 6MWD initially increased and then
stabilised over time with bosentan monotherapy (ﬁgure 2A).
For patients without Down syndrome who were treated
with bosentan monotherapy, the changes in 6MWD
from baseline were signiﬁcant at each time point up to
month 24 (ﬁgure 2B). For patients with Down syndrome
the change in 6MWD from baseline was not signiﬁcant
at any time point. 6MWD data for patients on sildenaﬁl
monotherapy are not described due to small patient
numbers (n=2). It is important to note that assessment
of response in patients with Down syndrome can be difﬁ-
cult to determine, as it is usually dependent on clinical
symptoms and the views of those caring for the patient.
Evidence that patients with Down syndrome respond less
well to PAH-speciﬁc therapy may have more to do with
the difﬁculty in assessing response than to any intrinsic
difference in response to therapy compared with
non-Down syndrome patients.
Of the 10 patients without Down syndrome who were
receiving dual therapy at the time of analysis, three were
excluded because they did not have treatment-naïve
baseline 6MWD data. For the seven patients with data,
6MWD at baseline was 246.3±73.0 m and 211.9±121.7 m
at the visit prior to receiving dual therapy, representing
a mean change of −34.4±124.3 m). 6MWD at last visit
was 214.4±96.9 m, representing a mean change of −31.9
±109.8 m from starting monotherapy (p=0.5) and of
+2.6±33.0 m (p=0.8) from the visit prior to receiving
dual therapy.
Mean pre and postwalk test oxygen saturations were
similar between patients without and with Down syn-
drome (table 3). There was no statistically signiﬁcant
relationship between change in prewalk test oxygen sat-
uration from baseline for all patients when analysed
together or by Down syndrome status over time. The
drop in oxygen saturation observed in the postwalk test
at baseline was similar in magnitude to the drop at all
time points. There was no evidence of a statistically sig-
niﬁcant difference between pre and postwalk test
oxygen saturation over time for patients overall or by
Down syndrome status.
With respect to laboratory parameters, mean AST
levels were within the normal range at each time point,
regardless of Down syndrome status (see online supple-
mentary table S1). One patient had an elevated level of
AST (267 U/L), although normal alanine aminotrans-
ferase level (42 U/L), at 18 months. There were no clin-
ical consequences and levels of AST returned to and
remained within normal levels for the 5 years of contin-
ued bosentan monotherapy. At all time points, mean
GGT levels were lower for patients with Down syndrome
compared with those without (see online supplementary
table S1) but were within the normal range for both
patient groups. Only patients on bosentan had sufﬁcient
GGT data available at each time point to analyse appro-
priately and levels were within the normal range at each
time point.
At all time points, mean haemoglobin levels were
within the normal range regardless of Down syndrome
status (see online supplementary table S1). Only
patients on bosentan had sufﬁcient haemoglobin data
available at each time point to analyse appropriately,
with haemoglobin levels within the normal range for
these patients at each time point. Mean platelet counts
were within the normal range (150–400×103/L) for
patients without Down syndrome at all time points but
were below normal range for patients with Down syn-
drome (see online supplementary table S1). This dispar-
ity was also reﬂected in patients on bosentan
monotherapy.
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Table 2 Baseline 6MWD, treatment duration and concomitant iron replacement therapy by treatment regimen
Treatment regimen
Bosentan monotherapy Sildenafil monotherapy Dual therapy
Monotherapy period Dual therapy period
Patient group
All patients, n 54 16 12
Non-Down syndrome patients, n 34 9 10
Down syndrome patients, n 20 7 2
Parameter Mean±SD 6MWD at baseline, m (median (range))
All patients (n=82) 268±109* (281 (29–480)*) 235±95 (254 (30–370)) 208±98† (210 (60–352)†)
Non-Down syndrome patients (n=53) 287±112* (296 (29–480)*) 270±81 (270 (150–370)) 246±73† (230 (165–352)†)
Down syndrome patients (n=29) 236±97 (238 (71–405)) 190±99 (197 (30–300)) 74.5±20.5 (75 (60–89))
Mean±SD Treatment duration, years (median (range))
All patients (n=82) 2.7±1.8 (2.5 (0.1–6.9)) 1.1±1.2 (0.6 (0.0–3.7)) 2.4±1.5 (2.2 (0.2–4.4)) 1.4±1.3 (1.0 (0.0–3.8))
Non-Down syndrome patients (n=53) 3.0±1.8 (3.2 (0.1–6.1)) 1.1±1.2 (0.6 (0.0–3.6)) 2.2±1.6 (1.9 (0.2–4.4)) 1.5±1.4 (1.0 (0.0–3.8))
Down syndrome patients (n=29) 2.1±1.8 (1.7 (0.1–6.9)) 1.1±1.4 (0.5 (0.0–3.7)) 3.0±0.4 (3.0 (2.8–3.3)) 0.8±0.6 (0.8 (0.4–1.2))
Iron replacement therapy, n (%)
All patients (n=82) 7 (13.0) 0 4 (33.3)
Non-Down syndrome patients (n=53) 4 (11.8) 0 3 (30.0)
Down syndrome patients (n=29) 3 (15.0) 0 1 (50.0)
*Baseline 6MWD unavailable for one patient.
†Baseline 6MWD unavailable for three patients.
6MWD, 6 min walk distance.
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Over the follow-up period, 14 patients died, of whom
four had Down syndrome. 1, 2 and 3-year survival rates
for all patients from time of treatment initiation were
96%, 87% and 80%, respectively. For patients without
Down syndrome the rates were 100%, 89% and 81%,
respectively, and for those with Down syndrome they
were 88%, 83% and 83%, respectively (ﬁgure 3). Cause
of death varied and included sudden cardiac death, pro-
gressive right heart failure and death from thrombo-
embolic complications.
DISCUSSION
We have previously reported the outcomes of patients
with PAH-CHD treated with bosentan monotherapy at
our centre.16 The present analysis expands on these
ﬁndings with outcomes from a larger number of
patients, over a longer time period and with additional
treatment regimens of sildenaﬁl monotherapy and dual
therapy with bostenan and sildenaﬁl. Our ﬁndings show
that, in patients with PAH-CHD, oral PAH-speciﬁc ther-
apies signiﬁcantly increase exercise capacity, measured
by 6MWD, above baseline over the ﬁrst 6 months of
treatment with stabilisation up to 2 years. This is broadly
consistent with other reports from the literature.17–21
Also consistent with other reports are the ﬁndings that
patients with Down syndrome walk shorter distances at
baseline and during treatment.18 20 We also observed a
deterioration in exercise capacity beyond 2 years.
Deterioration in 6MWD was not observed after a median
follow-up of 3 years in a retrospective analysis in patients
with Eisenmenger syndrome.21 However, 22% of patients
in this study had treatment escalation (ie, increased
dose or addition of a second therapy) after a median of
2.5 years.21 In our analysis, patients treated with dual
therapy had a decrease in 6MWD from baseline preced-
ing initiation of a second therapy, which although arrest-
ing deterioration in exercise capacity did not increase it
to above predeterioration levels. This is in contrast to
the ﬁndings of a recent prospective study, in which
Figure 1 (A) Absolute and (B)
change from baseline in 6 min
walk distance over time for all
patients and by Down syndrome
status. For the patients who had
data post 24 months the mean
±SD treatment duration from
commencement of therapy to the
latest time point was 4.1±1.1
(median 3.9 years, range 2.5–
6.9 years) for all patients (n=38),
4.1±1.1 (median 3.8 years, range
2.5–6.1 years) for patients without
Down syndrome (n=29) and 4.2
±1.2 (median 4.0 years, range
2.6–6.9 years) for patients with
Down syndrome (n=9). p Values
tested whether change in 6MWD
from baseline at each time point
was significantly different from no
change; *p<0.05, ***p<0.0001.
6MWD, 6 min walk distance; DS,
Down syndrome.
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increases in 6MWD in patients with PAH and
Eisenmenger syndrome were observed when sildenaﬁl
was added to bosentan in patients failing monother-
apy.22 Our analysis, which is based on real-life observa-
tions rather than a rigorously controlled study, shows
most patients do well on monotherapy while some
require dual therapy and tend to have a modest
response.
The drop in oxygen saturation from pre to postwalk
test was consistent from baseline and at all time points.
While treatment does not appear to increase postwalk test
saturations it also does not substantially decrease them,
thus supporting previous ﬁndings that PAH-speciﬁc ther-
apies do not cause right-to-left shunting.8
Our analysis revealed no worrisome safety signals with
regards to liver function and haematology during treat-
ment. The observation of below normal platelet counts
in patients with Down syndrome in our study is consist-
ent with reports of abnormal haematology in this patient
group.23 While platelet count is often abnormal in
patients with Down syndrome, haemoglobin levels are
usually in the normal range (13.0–18.0 g/dL in adult
males and 11.5–16.5 g/dL in adult, non-pregnant
females), although levels can also be lower and higher
than normal.23 We observed no difference in haemoglo-
bin levels between patients with and without Down syn-
drome, although mean values for all patients were
slightly above the upper limits of the normal range, sug-
gesting that in patients with PAH-CHD a higher value
represents a normal mechanism for maintaining tissue
oxygenation. It was not possible to measure the survival
of patients from diagnosis because diagnosis was not
always made at the time of therapy initiation in our
centre. Rather, we measured survival over the treatment
period. The estimated 3-year survival rates of 80% for all
patients analysed in our study are in line with ﬁndings
from the Registry to Evaluate Early and Long-Term PAH
Disease Management (REVEAL) of 4-year survival esti-
mates from enrolment of 77% in patients with
Eisenmenger syndrome and of 76% in patients with
Figure 2 (A) Absolute and B)
change from baseline in 6 min
walk distance over time for
patients on bosentan
monotherapy by Down syndrome
status. For the patients who had
data post 24 months the mean
±SD treatment duration from
commencement of bosentan
monotherapy to the latest time
point was 4.1±1.1 (median
3.8 years, range 2.5–6.1 years)
for patients without Down
syndrome (n=21) and 4.5
±1.5 years (median 4.4 years,
range 2.6–6.9 years) for patients
with Down syndrome (n=6). p
Values tested whether change in
6MWD from baseline at each time
point was significantly different
from no change; **p<0.001,
***p<0.0001. 6MWD, 6 min walk
distance; DS, Down syndrome.
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Table 3 Pre and postwalk test oxygen saturation and change in oxygen saturation over time for all patients and by Down
syndrome status
All patients (n=82) Non-Down syndrome patients (n=53) Down syndrome patients (n=29)
Mean±SD oxygen saturation (%) measured prewalk test (median (range))
Baseline 84.7±6.55 (84 (71–98))
n=78
84.9±6.59 (85 (71–97))
n=49
84.3±6.58 (83 (72–98))
n=29
3 months 85.5±6.24 (86 (70–98))
n=65
86.2±6.20 (87 (70–98))
n=44
84.2±6.26 (83 (73–96))
n=21
6 months 84.9±6.92 (85 (68–100))
n=66
85.0±7.20 (85 (68–100))
n=45
84.6±6.43 (84 (75–96))
n=21
12 months 85.6±7.17 (85 (70–98))
n=60
86.0±7.40 (85 (70–98))
n=42
84.7±6.70 (85 (72–95))
n=18
18 months 85.5±6.96 (87 (73–98))
n=52
85.1±7.01 (86 (73–98))
n=35
86.5±6.96 (87 (73–98))
n=17
24 months 86.1±7.45 (88 (64–100))
n=43
85.7±7.91 (88 (64–99))
n=30
86.8±7.45 (88 (64–100))
n=13
Latest 83.5±7.72 (83 (67–99))
n=37
84.4±8.16 (84 (67–99))
n=28
80.7±5.63 (79 (75–91))
n=9
Mean±SD oxygen saturation (%) measured postwalk test (median (range))
Baseline 72.0±12.78 (72 (39–99))
n=78
72.2±13.21 (70 (41–99))
n=49
71.7±12.23 (73 (39–99))
n=29
3 months 73.1±11.11 (72 (50–98))
n=65
74.9±10.81 (75 (53–95))
n=44
69.3±11.0 (69 (50–98))
n=21
6 months 72.4±10.95 (72 (48–96))
n=66
72.6±12.44 (72 (48–96))
n=44
72.2±7.00 (72 (59–85))
n=21
12 months 71.2±11.78 (70 (44–97))
n=59
71.7±11.69 (70 (53–97))
n=41
69.9±12.24 (72 (44–86))
n=18
18 months 70.3±11.17 (69 (42–96))
n=52
70.4±10.28 (71 (50–93))
n=35
69.9±13.16 (65 (42–96))
n=17
24 months 72.7±12.34 (72 (51–109))
n=42
72.2±11.66 (70 (51–95))
n=29
73.8±14.17 (73 (55–109))
n=13
Latest 69.9±10.82 (70 (53–95))
n=37
71.6±10.96 (71 (53–95))
n=28
64.7±8.97 (63 (55–81))
n=9
Figure 3 Survival from
treatment initiation for all patients
and by Down syndrome status.
DS, Down syndrome.
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PAH-CHD with unrepaired lesions.24 The 3-year esti-
mates of 81% in patients without Down syndrome and
of 83% in patients with Down syndrome are consistent
with 4-year survival estimates from study entry of 72%
and 80% in patients with PAH-CHD without and with
Down syndrome.19
PAH is a rare condition and the diagnosis and man-
agement of patients tends to occur in designated pul-
monary hypertension centres. Data from these centres
on the disease course of the different PAH aetiologies
and the most appropriate management and treatment
strategies are often published and together with those
from clinical drug trials feed into international10 25 and
national management guidelines.26 Due to the complex-
ity of an underlying cardiac defect, patients with
PAH-CHD are often managed in centres able to provide
specialist care in congenital heart disease and pulmon-
ary hypertension. Our patients were treated in accord-
ance with the most currently available management10 25
and commissioning27 guidelines. As such, the real-life
data collected over a period of 7 years reﬂect the treat-
ment and outcomes of patients within the recom-
mended approaches that prevailed during this time.
Bosentan monotherapy was the most frequently pre-
scribed PAH-medication for patients without and with
Down syndrome and prescribed for the longest time
period. This approach is based on data from the
BREATHE-5 trial of bosentan in Eisenmenger syndrome,
which constitutes the earliest piece of rigorous evidence
for the safety and efﬁcacy of a PAH therapy in patients
with PAH-CHD.8 Our database also included patients who
received sildenaﬁl monotherapy in more recent years. This
reﬂects updated guidelines25 that give equal support to
phosphodiesterase inhibitors and ERAs as ﬁrst-line treat-
ments for patients with PAH (in functional class III).
Proportionally there are more patients with Down syn-
drome on sildenaﬁl than patients without Down syndrome.
This may be due to the necessity for frequent blood tests
for liver function monitoring with ERAs, which might be
difﬁcult to obtain in some patients with Down syndrome.
The initiation of additional therapy is a relatively
recent development at this centre and it has only been
undertaken in a relatively small number of patients. PAH
treatment guidelines currently give recommendations of
when to initiate sequential combination therapy based
on prognostic factors and treatment goals associated
with an improved prognosis.25 However, in patients with
PAH-CHD, prognostic factors such as right heart failure
may not be as relevant as in idiopathic PAH. Moreover,
the values set for treatment goals for 6MWD and cardio-
pulmonary and echocardiographic parameters are based
on data from other PAH aetiologies and may not be the
same for patients with PAH-CHD. While study data from
the most experienced centres show combination therapy
is used in patients with PAH-CHD,15 27 how widely it is
used in less experienced centres is unknown as such
centres rarely publish data. To encourage the uptake of
dual therapy, more speciﬁc evidence and advice on when
to initiate a second therapy in patients with PAH-CHD
are required.
This is a retrospective analysis of data collected during
routine clinical practice and is based on real-life observa-
tions. As such patients were not randomised and there
were no matched controls. The principal limitation of
our study is missing data at certain time points, either
because patients missed a visit or because they had not
been on treatment long enough to contribute to the
time point analysed. Due to small patient numbers and
missing data we were not able to rigorously analyse data
from patients on sildenaﬁl monotherapy.
In conclusion, our data show that in patients with
PAH-CHD treated with oral PAH therapies in a specia-
lised congenital heart disease centre, monotherapy with
a PAH-speciﬁc medication seems to be effective in the
vast majority of patients with PAH-CHD, and add-on
therapy, while preventing decline, does not increase
exercise tolerance. However, our data highlight the need
for more evidence of when to initiate dual therapy in
patients with PAH-CHD.
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